Participated · Seed · Mar 2026

Theta Neurotech is developing a non-invasive wearable EEG patch aimed at forecasting seizures. The company pivoted from a broader consumer "Fitbit for the brain" concept toward a medical wedge focused on epilepsy after identifying clinical demand and behavioral considerations for EEG wearables. Theta has raised $2 million in pre-seed funding to support device development, machine-learning research, and an exploratory clinical study. Co-founders Truman Pierson and Christopher Fitz lead the company. The market for seizure monitoring includes invasive and non-invasive competitors, but non-invasive seizure forecasting remains early-stage and challenging. Several rivals are running exploratory studies, and none have yet reached patients.

Participated · Equity · Jan 2026

iSono Health is a commercial-stage medical technology company focused on transforming women’s breast imaging with ATUSA™, an FDA-cleared, portable and hands-free 3D ultrasound platform. The system captures full-breast volumes in about two minutes per breast—roughly ten times faster than manual handheld ultrasound—and delivers consistent images independent of the operator’s skill. By pairing its wearable hardware with cloud-based intelligence, the company offers an "Ultrasound-as-a-Service" model that lowers upfront costs for clinics and generates recurring revenue. iSono is advancing an AI "sentient partner" roadmap to provide real-time diagnostic support and is running the 800-patient, NIH-funded AUDIBLE Study to validate its algorithms against mammography and MRI. The company has secured multiple paying clinics through a Pioneering Partner Program and earned industry recognition such as HLTH 2025 Rising Star (Diagnostics) and WISH 2024 Global Awards. Financially, iSono has raised $14.7 million across venture rounds and non-dilutive grants, including a recent $3 million Seed Preferred round and $3.7 million from NIH, NSF and NCI. These funds position the firm to scale global deployments while continuing clinical validation.

Participated · Seed · May 2025

Pulse Charter Connect (PCC) is a healthcare logistics company led by CEO and Founder Laura Epstein that focuses on coordinating organ and surgical team transportation. Its platform leverages real-time data and automation to minimize delays and streamline the organ transplant process. The company raised $2M in Seed funding to support expansion of operations and continued product development. The round was led by Ivy Ventures and Simplex Ventures with participation from Cedars Sinai Health Ventures, Belal Badat Ventures, Techstars, The Josephine Collective and strategic angel investors. This financing increased the startup’s total capital raised to $3.3M. The article does not disclose additional operating metrics or other financing instruments.

Participated · Equity · May 2022

Line issues instant emergency cash lines — as little as $10 — without interest or proof of credit history, and increases customers' access over time as they repay. The service is subscription-based (starting at $1.97/month) and functions as a revolving line: users often repay within the same month and can immediately reuse their line. Line says it came out of stealth last July and has 500,000 registrants across more than 5,200 cities in all 50 states, with registrations growing 100% month over month. The startup reports it is profitable and that revenue is growing 300% quarter over quarter. Its user base is roughly 60% women, and the internal team is 40% women; parity is an explicit goal. Line’s underwriting and algorithm weigh factors like inflation, caretaking responsibilities, and hourly jobs to tailor access, and the founder has positioned the company as mission-driven and not a neobank.